ensure IMPs are administered according to protocol and stored appropriately.

FDA 21 CFR Part 312.57: Sponsors must maintain records of shipment and disposition, including site-level accountability.

ICH E6(R3) Section 4.6: Investigators are responsible for IMP accountability at the site, including storage, use, and return.

EMA GDP: Extends GDP principles to investigator sites, requiring documented SOPs and monitoring practices.

WHO emphasizes the importance of training site staff in GDP and GCP principles, ensuring that investigational supplies are managed with the same rigor as commercial drug products.

Audit Findings in Site Supply Oversight

Common site-level deficiencies identified during audits include:

Audit Finding	Root Cause	Impact
Missing accountability logs	Manual recordkeeping errors	Data integrity risk
Unmonitored site refrigerators	No calibration or data loggers	Product degradation, FDA observation
Untrained site staff	No documented GDP training	Protocol deviations
Improper destruction of IMPs	No return-to-sponsor procedures	Regulatory non-compliance

Example: In a Phase II cardiovascular trial, FDA inspectors noted unreconciled IMPs at two investigator sites. The sponsor received a Form 483 and was required to retrain staff and implement monthly reconciliation.

Root Causes of Site Supply Failures

Root causes typically include:

• Over-reliance on manual accountability logs without electronic backup.
• Insufficient training of site pharmacists and coordinators.
• Lack of sponsor oversight and monitoring of site supply processes.
• Inadequate SOPs for receipt, storage, and return of IMPs.

Case Example: In a rare disease study, returned IMPs were destroyed by site staff without sponsor authorization. Root cause analysis revealed no SOPs defining return procedures and poor sponsor oversight.

Corrective and Preventive Actions (CAPA) for Site Supply Oversight

Sponsors must implement structured CAPA frameworks to address site supply deficiencies:

1. Immediate Correction: Reconcile IMP inventories, quarantine impacted stock, and retrain site staff.
2. Root Cause Analysis: Identify whether failures stem from training gaps, SOP deficiencies, or lack of sponsor oversight.
3. Corrective Actions: Update SOPs, introduce electronic accountability systems, and increase site monitoring frequency.
4. Preventive Actions: Establish annual site audits, mandate GDP/GCP refresher training, and integrate site supply into centralized dashboards.

Example: A sponsor introduced an electronic site supply management system linked to their CTMS and IRT. This reduced reconciliation errors by 90% and improved FDA inspection outcomes.

Best Practices in Site Supply Management

To ensure compliance, US sponsors should adopt the following best practices:

• ✔️ Provide electronic accountability tools to all investigator sites.
• ✔️ Validate and calibrate site refrigerators and freezers annually.
• ✔️ Train site pharmacists and coordinators in GDP/GCP every year.
• ✔️ Archive supply-related documentation in the Trial Master File (TMF).
• ✔️ Include site supply checks in monitoring visit reports.

Suggested KPIs for monitoring site supply:

KPI	Target	Relevance
Reconciliation accuracy	100%	21 CFR Part 312 compliance
Staff training completion	100%	Inspection readiness
Temperature monitoring compliance	100%	GDP expectations
Audit findings related to site supply	<1 per trial	QMS effectiveness

Case Studies of Site Supply Deficiencies

Case 1: FDA inspection in an oncology trial cited missing site accountability logs, requiring CAPA before study continuation.
Case 2: EMA inspection found untrained pharmacists handling IMPs in a rare disease trial, leading to protocol deviations.
Case 3: WHO audit highlighted absence of return SOPs in African sites, resulting in IMP destruction without sponsor authorization.

Conclusion: Strengthening Site Supply as a Compliance Pillar

Site supply management is a high-risk compliance area requiring proactive oversight. For US sponsors, FDA expects complete IMP accountability, staff training, and documented storage conditions at every site. By embedding CAPA, digitization, and monitoring into site supply processes, sponsors can ensure inspection readiness and protect patient safety.

Ultimately, sites are not just trial locations—they are compliance partners. Sponsors must treat site supply oversight as a regulatory priority to ensure trial success and data credibility.